ライフサイエンスコーパス: bone mineral density

1 after treatment started (including data for bone mineral density).

2 at individuals with RTS have decreased areal bone mineral density.

3 ea, but there were no such associations with bone mineral density.

4 sa that is independent of that provided with bone mineral density.

5 e surface, accompanied by a dramatic loss of bone mineral density.

6 ut not CD8+ T cells significantly diminished bone mineral density.

7 ears in a Women's Health Initiative study of bone mineral density.

8 n associated with renal toxicity and reduced bone mineral density.

9 libido, vasomotor instability, and decreased bone mineral density.

10 ion, and then develop anemia and a decreased bone mineral density.

11 omy-induced osteoporosis results in improved bone mineral density.

12 exposure were independent predictors of low bone mineral density.

13 evious aromatase inhibitor use, and baseline bone mineral density.

14 n IBD patients and to IBD-associated loss of bone mineral density.

15 sumab, however, results in rapidly declining bone mineral density.

16 r trabecular number, connective density, and bone mineral density.

17 95% CI -0.01, 0.01]; p = 0.80; n = 127,587); bone mineral density (0.01 g/cm(2) [95% CI -0.01, 0.03];

18 ct of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth.

19 A significant decrease in global trabecular bone mineral density (38.1%) and cortical thickness (13.

20 al women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the l

21 The pathogenesis of declining bone mineral density, a universal feature of ageing, is

22 Bone mineral density, abdominal fat area, and paraspinal

23 Although areal bone mineral density (aBMD) assessed by dual-energy x-ra

24 trations of several PFASs and measured areal bone mineral density (aBMD) by dual-energy X-ray absorpt

25 are variables that are not captured by areal bone mineral density (aBMD), and dietary protein intakes

26 Bone mineral density after reaching skeletal maturity is

27 Of six adults that were subjected to bone mineral density analysis, three presented with oste

28 eal (P=0.001) and volumetric (P<0.001-0.006) bone mineral density and 1.5- to 1.8-fold increases in r

29 Canagliflozin is associated with decreased bone mineral density and a potential increased risk for

30 Bone mineral density and abdominal fat and paraspinal mu

31 Alveolar bone mineral density and alveolar bone volume were quant

32 ghly prevalent disorder characterized by low bone mineral density and an increased risk of fracture,

33 with or without potassium citrate had higher bone mineral density and better mechanical properties th

34 r alafenamide had more favourable effects on bone mineral density and biomarkers of renal safety than

35 not dwarfed and had significantly increased bone mineral density and bone mineral content in femurs

36 ation and finite element analysis to measure bone mineral density and bone strength at the hip and sp

37 osure to 20 mg/kg fluoxetine reduced femoral bone mineral density and bone volume fraction, negativel

38 I) is a genetic disorder that results in low bone mineral density and brittle bones.

39 inflammation was associated with declines in bone mineral density and cancellous bone volume.

40 ascular volume, type H vessel formation, and bone mineral density and contents, as well as BV/TV, Tb.

41 Conclusion In addition to bone mineral density and geometry of the proximal femur,

42 Hip and spine bone mineral density and glomerular filtration were each

43 Patients with type 1 diabetes have lower bone mineral density and higher risk of fractures.

44 Patients also suffer from decreased bone mineral density and increased fracture risk.

45 g from autism have been reported to have low bone mineral density and increased risk for fracture, ye

46 genetic factors with pleiotropic effects on bone mineral density and lean mass.Bone mineral density

47 ffects on bone mineral density and lean mass.Bone mineral density and lean skeletal mass are heritabl

48 mine if computed tomographic (CT) metrics of bone mineral density and muscle mass can improve the pre

49 L5HU and PsoasL4-5, which are surrogates for bone mineral density and muscle mass, respectively, were

50 ignificantly higher bone volume/total volume bone mineral density and number of osteoblasts in the ra

51 We prespecified six secondary bone mineral density and renal biomarker safety endpoint

52 disoproxil fumarate in all six prespecified bone mineral density and renal biomarker safety endpoint

53 nce of viral suppression and led to improved bone mineral density and renal function.

54 In this population-based cohort study, bone mineral density and risk factors were used to calcu

55 istal radius was performed and evaluated for bone mineral density and trabecular and cortical bone mi

56 osterone had beneficial effects on increased bone mineral density, and decreased body fat; adverse ef

57 ice by adoptive transfer, and bone turnover, bone mineral density, and indices of bone structure and

58 howed a reduction of trabecular bone volume, bone mineral density, and number and thickness in KO mic

59 Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the U.S. popul

60 in other frailty measures, body composition, bone mineral density, and physical functions.

61 r and hemi-mandible bone mineral content and bone mineral density, and trabeculae number were similar

62 Osteopenia, osteoporosis, and low bone mineral density are frequent in patients with HIV.

63 ithms that combine clinical risk factors and bone mineral density are now widely used in clinical pra

64 Most interventions used bone mineral density as a surrogate outcome, despite com

65 We assessed the 96 week loss of bone mineral density associated with a nucleoside or nuc

66 of a CpG site proximal to the NFIX locus and bone mineral density at age 17.

67 mide had a significantly smaller decrease in bone mineral density at hip (mean change -0.10% [95% CI

68 01), and a significantly smaller decrease in bone mineral density at spine (mean % change -1.30 vs -2

69 ry, ECSW was associated with preservation of bone mineral density at the central skeleton; however, i

70 t was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months.

71 Bone mineral density at the spine, hip, and wrist were m

72 , vs. 55.0 to 52.3 kg [5% decrease]), as did bone mineral density at the total hip (grams per square

73 ciation between serum PFAS concentration and bone mineral density at total femur (TFBMD), femoral nec

74 entage changes in lumbar spine and total hip bone mineral density at week 48, assessed by dual energy

75 rnib monotherapy treatment reveal additional bone mineral density benefit but likely no added cardiov

76 Condylar bone mineral density (BMD) (computed tomography Hounsfie

77 in Z mRNA level strongly correlated with low bone mineral density (BMD) (g/cm(2)), lumbar spine L2-L4

78 We searched for variants associated with bone mineral density (BMD) after enriching the discovery

79 oporosis is a condition characterized by low bone mineral density (BMD) and an increased risk of frac

80 n about the effects of eradication of HCV on bone mineral density (BMD) and biomarkers of bone remode

81 Bone mineral density (BMD) and bone mineral content (BMC

82 ondition associated with progressive loss of bone mineral density (BMD) and compromised bone strength

83 ody mass, shortened body length, and reduced bone mineral density (BMD) and content (BMC) first evide

84 Trabecular and cortical bone mineral density (BMD) and content were assessed at

85 of soft-tissue parameters were compared with bone mineral density (BMD) and cortical bone thickness.

86 c skeletal disorder characterized by reduced bone mineral density (BMD) and disrupted bone architectu

87 using computed tomography thoracic vertebral bone mineral density (BMD) and fracture prevalence among

88 ociation studies (GWASs) identified multiple bone mineral density (BMD) and fracture-associated loci.

89 hoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes po

90 have increased fracture risk, despite normal bone mineral density (BMD) and high BMI-factors that are

91 tary patterns that explain most variation in bone mineral density (BMD) and hip bone geometry are ass

92 tis C virus (HCV) is associated with reduced bone mineral density (BMD) and increased fracture rates,

93 g CAC progression, including measurements of bone mineral density (BMD) and novel bone markers in adu

94 The association between low bone mineral density (BMD) and periodontitis in perimeno

95 Whether PM is associated with loss of bone mineral density (BMD) and risk of bone fractures is

96 Children with cancer may develop low bone mineral density (BMD) any time before or after diag

97 Bone mineral content (BMC) and bone mineral density (BMD) are positively correlated wit

98 ndependently predict fracture risk and, with bone mineral density (BMD) assessed by X-ray (DXA), may

99 one density contributing to lower volumetric bone mineral density (BMD) at both distal radius and tib

100 tion values across all adult ages to measure bone mineral density (BMD) at routine CT.

101 hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hi

102 ce imaging in 215 healthy army recruits, and bone mineral density (BMD) by Dual X-Ray Absorptiometry

103 Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorpti

104 Derangement in bone mineral density (BMD) caused by glucocorticoid is w

105 Bone mineral density (BMD) changes and fracture rate.

106 We compared adjusted bone mineral density (BMD) changes between human immunod

107 ave a protective effect on lumbar spine (LS) bone mineral density (BMD) compared with lower protein i

108 Background Bone mineral density (BMD) could be derived from CT loca

109 Bone mineral density (BMD) derived from cardiac CT may b

110 Little is known about bone mineral density (BMD) during pregnancy.

111 s-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil f

112 endpoint was percentage change in total hip bone mineral density (BMD) from baseline to week 48 in t

113 g the effect of vitamin D supplementation on bone mineral density (BMD) have yielded conflicting resu

114 genetic risk factors (GRFs) for fracture and bone mineral density (BMD) identified from people of Eur

115 an mass (ALM), quadriceps strength (QS), and bone mineral density (BMD) in 2986 men and women, aged 1

116 ed lumbar spine, total hip, and femoral neck bone mineral density (BMD) in 581 HIV-positive (94.7% re

117 identified more than 60 loci associated with bone mineral density (BMD) in adults but less is known a

118 leotide polymorphisms (SNPs) associated with bone mineral density (BMD) in adults.

119 nonalcoholic fatty liver disease (NAFLD) and bone mineral density (BMD) in children or adolescents, b

120 Initiation of TDF decreases bone mineral density (BMD) in HIV-infected people.

121 ine the effect of calcium supplementation on bone mineral density (BMD) in lactating women.

122 Weight loss (WL) negatively affects bone mineral density (BMD) in older populations and has

123 We aimed to evaluate bone mineral density (BMD) in patients with scoliosis by

124 (FES) standing system for rehabilitation of bone mineral density (BMD) in people with Spinal Cord In

125 in osteoprotegerin correlate with decreased bone mineral density (BMD) in untreated HIV infection.

126 monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal

127 Background: Bone mineral density (BMD) is a heritable phenotype that

128 Background: Whether change in bone mineral density (BMD) is an accurate indicator of a

129 High bone mineral density (BMD) is associated with an increas

130 Bone mineral density (BMD) is highly heritable, a major

131 (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation.

132 [control (CON)].RCE significantly attenuated bone mineral density (BMD) loss at the L2-L4 lumbar spin

133 -analysis examining isoflavone therapies and bone mineral density (BMD) loss in peri- and postmenopau

134 eficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of oste

135 ted (PHIV) children and adolescents with low bone mineral density (BMD) may be at higher risk of oste

136 Bone mineral density (BMD) measured by dual-energy x-ray

137 Bone mineral density (BMD) measurement by dual-energy x-

138 titative ultrasonography (QUS) in predicting bone mineral density (BMD) reduction in a population of

139 g-reported parental hip fracture in a unique bone mineral density (BMD) registry linked to administra

140 sulting in larger increases in hip and spine bone mineral density (BMD) than with either drug alone.

141 diac CT can be used to help measure thoracic bone mineral density (BMD) to identify individuals who h

142 lumbar spine bone mineral content (BMC) and bone mineral density (BMD) was assessed using DXA.

143 Trabecular bone mineral density (BMD) was determined in each verteb

144 Bone mineral density (BMD) was measured using DXA.

145 nd whole-body bone mineral content (BMC) and bone mineral density (BMD) were measured at age 20 y thr

146 Plasma bone turnover markers and bone mineral density (BMD) were performed at weeks 0, 12

147 Plasma bone turnover markers and bone mineral density (BMD) were quantified at weeks 0, 1

148 ated deficiencies and cardiovascular health, bone mineral density (BMD), and physical fitness.

149 ally relevant to osteoporosis, assessed from bone mineral density (BMD), as a new potential target of

150 content and density, cortical and trabecular bone mineral density (BMD), BMC, and bone area at the 4%

151 stigated their prospective associations with bone mineral density (BMD), bone area, and bone mineral

152 ions between changes in areal and volumetric bone mineral density (BMD), bone microstructure and stre

153 Offspring total body bone mineral density (BMD), bone mineral content (BMC),

154 by ultrasound examination; bone retraction, bone mineral density (BMD), bone volume/tissue volume (B

155 red genetic signals robustly associated with bone mineral density (BMD), but not the precise localiza

156 ially vegan diets, are associated with lower bone mineral density (BMD), but this does not appear to

157 o, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in pat

158 ootball after 6 months, hip and lumbar spine bone mineral density (BMD), mental health score, fat and

159 orted that geographical variation influences bone mineral density (BMD), obesity, and sarcopenia rela

160 ions aimed at preventing fracture, improving bone mineral density (BMD), or preventing or delaying os

161 the patients showed an increase in fitness, bone mineral density (BMD), quality of life and a decrea

162 tion between B-vitamin status biomarkers and bone mineral density (BMD), risk of osteoporosis, and bi

163 bl-Wnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly b

164 were accompanied by diminishing weight loss, bone mineral density (BMD), trabecular thickness, trabec

165 soprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium abso

166 S dataset from subjects with low versus high bone mineral density (BMD), we recovered methylation val

167 However, obese people have a higher bone mineral density (BMD), which suggests that low 25(O

168 The primary outcome was total hip bone mineral density (BMD), with femoral neck BMD, lumba

169 The reference standard was a bone mineral density (BMD)-based Fracture Risk Assessmen

170 isease diagnosed primarily by measurement of bone mineral density (BMD).

171 linically relevant, significant decreases in bone mineral density (BMD).

172 elationship of those variables to changes in bone mineral density (BMD).

173 ide association studies are also involved in bone mineral density (BMD).

174 nfection is associated with 2% to 6% loss of bone mineral density (BMD).

175 useful tools to screen for reduced skeletal bone mineral density (BMD).

176 LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral density (BMD).

177 in low estrogen levels, which in turn affect bone mineral density (BMD).

178 actor for osteoporotic fractures and altered bone mineral density (BMD).

179 volume (BV), bone mineral content (BMC), and bone mineral density (BMD).

180 ng-related disease diagnosed primarily using bone mineral density (BMD).

181 e-wide association study summary datasets of bone mineral density (BMD).

182 Individuals who share the same bone-mineral density (BMD) vary in their fracture risk,

183 ne strength (indicated by fracture and lower bone mineral density, BMD) is associated with subsistenc

184 DXA (reference standard) to determine areal bone mineral densities (BMDs), and (c) quantitative CT w

185 1 y of age and in a subgroup at 2 y of age : Bone mineral density, bone mineral content (BMC), area-a

186 Spinal loading significantly increased bone mineral density, bone mineral content, and bone are

187 p-null (Bsp(-/-)) mice exhibit reductions in bone mineral density, bone turnover, osteoclast activati

188 d a smaller decrease in lumbar spine and hip bone mineral density but greater accumulation of limb an

189 ances (PFASs) has been associated with lower bone mineral density, but data are limited, particularly

190 tients with chronic hepatitis B have reduced bone mineral density, but the reduction is limited to 1

191 micro-computed tomographic (CT) imaging and bone mineral density by peripheral quantitative CT scann

192 ect to their metabolic bone status including bone mineral density, calcium kinetics studies, and mark

193 In resource-limited settings, FRAX without bone mineral density can be substituted for DXA.

194 deletion of Cx37 (Cx37(-/-)) exhibit higher bone mineral density, cancellous bone volume, and mechan

195 articipants were stratified by spine and hip bone mineral density categories.

196 absorptiometry (DEXA) was used to determine bone mineral density changes in TDF-exposed patients.

197 en switching from teriparatide to denosumab, bone mineral density continued to increase, whereas swit

198 nce of pathogenic variants in RECQL4 and low bone mineral density correlate with the history of incre

199 We also apply our approach to bone mineral density data, and again final models contai

200 The local trabecular bone mineral density decreased in both high stress and l

201 Bone mineral density decreased in the first 6 months, wi

202 There were no bone architectural or bone mineral density differences by microCT.

203 -wide association study (GWAS) for estimated bone mineral density (eBMD) identified 1103 independent

204 models, I(1670)/I(1640,) age, and volumetric bone mineral density explained 50.2% (microscope) and 49

205 her fracture genetic risk score (Fx-GRS) and bone mineral density genetic risk score (BMD-GRS) modify

206 nd was associated with a smaller decrease in bone mineral density; however, greater resistance and ga

207 er group; we instead observed an increase of bone mineral density in both lumbar spine and total hip

208 ations in Col6a5 that underlies variation in bone mineral density in both mouse and human.

209 ested a trend of less vertical bone gain and bone mineral density in controls (P >0.05).

210 sing and has been linked to both obesity and bone mineral density in humans by genome-wide associatio

211 t testosterone replacement therapy increases bone mineral density in hypogonadal men, including men w

212 restores reproductive capacity and increases bone mineral density in patients with hypothalamic ameno

213 tch study, we aimed to assess the changes in bone mineral density in postmenopausal osteoporotic wome

214 ous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bo

215 At week 48, the mean percentage loss in bone mineral density in the lumbar spine was greater in

216 ze that an observed decrease in genetic heel bone mineral density in the Neolithic reflects adaptatio

217 nes were significantly associated with spine bone mineral density, including BDNF, PDE4D, and SATB2,

218 48 months, the primary outcome of mean spine bone mineral density increased by 18.3% (95% CI 14.9-21.

219 Similarly, femoral neck bone mineral density increased more in the teriparatide

220 ineral density secondary outcomes, total hip bone mineral density increased more in the teriparatide

221 ion Combined assessment of bone strength and bone mineral density is a cost-effective strategy for os

222 Low bone mineral density is an independent and significant p

223 Systemic and persistent low bone mineral density is an independent prognostic factor

224 uce fragility fractures in patients with low bone mineral density is beyond the scope of the guidelin

225 ar growth attenuation and adverse effects on bone mineral density is generally low but should be cons

226 Bone mineral density is known to be a heritable, polygen

227 The pathogenesis of declining bone mineral density is poorly understood but it is inhe

228 ovements in blood pressure, body mass index, bone mineral density, lipid levels, or quality-of-life m

229 s in eight loci, including seven established bone mineral density loci: WNT4, GALNT3, MEPE, CPED1/WNT

230 y, whereas ST-SPI diet only reduced cortical bone mineral density loss 3 wk post-OVX.

231 cant component of the pathophysiology of the bone mineral density loss associated with Inflammatory B

232 efficacy but with decreased renal injury and bone mineral density loss compared with TDF.

233 Bone mineral density loss has been described in TDF-trea

234 Total hip bone mineral density loss was similarly greater at week

235 ogesterone acetate (DMPA) is associated with bone mineral density loss.

236 nclusion Experimental evidence suggests that bone mineral density measurements are accurate and preci

237 Clinical and laboratory parameters, bone mineral density, microarchitecture, and vertebral f

238 splay skeletal alterations including reduced bone mineral density, modified bone structure and distin

239 ombined teriparatide and denosumab increased bone mineral density more than either drug alone.

240 Other than increased bone mineral density, no improvement rates exceeded thos

241 f fluoride's effects showed some increase in bone mineral density of adolescents and young adults in

242 Small reductions (<2%) in mean bone mineral density of hip and spine were detected by d

243 We aimed to investigate the effect on bone mineral density of switching from a regimen contain

244 Notably, bone mineral density, osteoporosis and osteoporotic frac

245 e percent change in posterior-anterior spine bone mineral density over 4 years.

246 The significantly improved bone mineral density, overall safety, and efficacy data

247 Despite normal to high bone mineral density, patients with type 2 diabetes (T2D

248 e revealed increased remodelling and reduced bone mineral density portrayed by increased carbonate to

249 we show that Ppia(-/-) mice demonstrate low bone mineral density, reduced osteoblast numbers, and in

250 , and suppression of ectopic calcifications, bone mineral density reduction, pulmonary emphysema and

251 ibia, bone mineral content (BMC), volumetric bone mineral density, robustness, and strength indexes w

252 For the bone mineral density secondary outcomes, total hip bone

253 users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vi

254 Lumbar spine bone mineral density showed a mean increase by day 85 an

255 revented the reduction in spinal and femoral bone mineral density, spinal bone volume/tissue volume,

256 ostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non

257 eplacement therapy has been shown to improve bone mineral density, studies have also linked bone loss

258 n increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibit

259 risk factors for osteoporotic fractures, and bone mineral density surveillance) originated from the q

260 e status, previous tamoxifen use, and lowest bone mineral density T score in the lumbosacral spine, t

261 commended in postmenopausal women who have a bone mineral density T score of -2.5 or less, a history

262 erate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1

263 For bone mineral density T scores at the femoral neck, biome

264 rs or more, with a femoral neck or total hip bone mineral density T-score between -2.5 and -4.0 if no

265 ient subgroups, including in patients with a bone mineral density T-score of -1 or higher at baseline

266 CI 0.31-0.64], p<0.0001) and in those with a bone mineral density T-score of less than -1 already at

267 y lean mass (TB-LM) and total-body less head bone mineral density (TBLH-BMD) regions in 10,414 childr

268 otic fracture, the clinician should obtain a bone mineral density test.

269 s associated with significantly less loss of bone mineral density than a standard regimen containing

270 urgery, the hind limb had significantly less bone mineral density than contralateral controls, confir

271 pids, and greater decreases from baseline in bone mineral density than did those who received placebo

272 ficantly smaller mean percentage declines in bone mineral density than those receiving tenofovir diso

273 d contributions to local processes including bone mineral density through candidate genes such as ost

274 hese mice displayed significant reduction in bone mineral density, trabecular bone volume, and cortic

275 ng bone disease that is characterised by low bone mineral density, typically assessed using dual-ener

276 ex, serum type I collagen C-telopeptide, hip bone mineral density, urticaria pigmentosa, and alcohol

277 oncentration, serum phosphate concentration, bone mineral density, vascular calcification, renal func

278 with a significant increase in femoral neck bone mineral density; vascular calcification remained un

279 These groups exhibited decreased bone mineral density, volume fraction, and bone formatio

280 ructure after 12 weeks follow-up covered the bone mineral density, -volume, -trabecular thickness and

281 p<0.0001), and mean percentage change in hip bone mineral density was 1.33% (2.20) in the elvitegravi

282 week 48, the mean percentage change in spine bone mineral density was 2.24% (SD 3.27) in the elvitegr

283 Bone mineral density was assessed in those patients with

284 Normal bone mineral density was detected in 2/8 case, osteopeni

285 Bone mineral density was measured at lumbar spine and th

286 Bone mineral density was measured at the lumbar spine an

287 DEXA for measuring bone mineral density was performed on every patient.

288 Concomitantly, alveolar bone mineral density was significantly lower in all thre

289 After 48 months, radius bone mineral density was unchanged in the teriparatide t

290 t mass, lean mass, bone mineral content, and bone mineral density, was determined by dual-energy X-ra

291 rial which tested the effect of denosumab on bone mineral density, we assessed the impact of this dru

292 Total and trabecular bone mineral density were significantly lower (-13.4% an

293 Texture parameters, but not bone mineral density, were associated with lowest lifeti

294 effects of elagolix, especially decreases in bone mineral density, were attenuated with add-back ther

295 the loss of total, trabecular, and cortical bone mineral density, whereas ST-SPI diet only reduced c

296 AS concentrations were associated with lower bone mineral density, which varied according to the spec

297 ce at routine CT to identify adults with low bone mineral density who are at risk for osteoporosis.

298 ge from baseline to week 48 in spine and hip bone mineral density with a null hypothesis of zero betw

299 usal associations between blood pressure and bone-mineral density with type 2 diabetes.

300 Mean bone mineral density z scores (lumbar spine and femur) r